-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Soraru Gianni
Editorial: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Specific antipsychotic drugs prescribed for dementia could increase mortality
News and Views: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design, findings and implications of the liraglutide Phase III clinical trial program
Bruce W Bode
Review: Clinical Trail Outcomes: Clinical Investigation